Advertisement


Scott Kopetz, MD, on Colorectal Cancer: Results of the SWOG 1406 Trial

2017 Gastrointestinal Cancers Symposium

Advertisement

Scott Kopetz, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (Abstract 520).



Related Videos

Gastroesophageal Cancer

Karyn A. Goodman, MD, on Esophageal Cancer: Results of CALGB 80803

Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).

Pancreatic Cancer

Sarah E. Hoffe, MD, on Pancreatic Cancer and SBRT: Pros and Cons

Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.

Gastrointestinal Cancer

Masanori Terashima, MD, PhD, on Gastric Cancer: Results of the JCOG1001 Trial

Masanori Terashima, MD, PhD, of Shizuoka Cancer Center, discusses phase III study findings evaluating bursectomy for patients with subserosal/serosal gastric cancer (Abstract 5).

Hepatobiliary Cancer

Julien Edeline, MD, on Biliary Tract Cancer: Results of the PRODIGY 12-ACCORD 18 Trial (French Language Version)

Julien Edeline, MD, of the Centre Eugène Marquis, discusses in French study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).

Colorectal Cancer

Brendan J. Guercio, MD, on Colorectal Cancer and Physical Activity: Impact on Survival

Brendan J. Guercio, MD, of the Dana-Farber Cancer Institute, discusses results from a study of patients with metastatic colorectal cancer who took part in weekly physical activity and its impact on their disease progression and overall survival (Abstract 659).

Advertisement

Advertisement




Advertisement